Probitas suspends plans to float

Probitas Pharma, a Barcelona-based plasma derivatives specialist, has recently postponed plans to list the company citing international stock market volatility and the difficulties of setting a suitable price for the stock. The firm raised a E90m round of funding from Secuoya Capital, the vehicle owned by SantanderCentral Hispano in late 2001. Secuoya Capital Privado has taken a minority stake in the company. Prior to the investment, Morgan Grenfell Private Equity owned a 45% equity stake in Probitas Pharma. Spanish shareholders control the remaining equity. The investment was made in order partially to finance the acquisition of Seracare Ltd, its main supplier of raw material in the US.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Southern Europe